(2R,3R,4S,5S)-2-[6-amino-2-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4S,5S)-2-[6-amino-2-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)oxolane-3,4-diol
• 化学式: C₂₂H₂₆N₈O₅
• 分子量: 482.5
• InChiKey: KCSJLURBGWEYEL-OGPXJPENSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  191
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1056759B1

  公开（公告）日：2002-09-04
• US6610665B1
  申请人：——

  公开号：US6610665B1

  公开（公告）日：2003-08-26
• [EN] METHOD OF DETERMINING SUSCEPTIBILITY TO DISEASES<br/>[FR] METHODE PERMETTANT DE DETERMINER LA RECEPTIVITE A CERTAINES MALADIES
  申请人：GLAXO GROUP LTD

  公开号：WO2002036816A2

  公开（公告）日：2002-05-10

  The present invention relates to polymorphisms in the adenosine 2a (A2a) human receptor gene, and to the use of such polymorphisms in the prognosis, diagnosis and treatment of diseases associated with said receptor eg. asthma, chronic obstructive pulmonary disease (COPD), motor dyskinesia disorders (such as Parkinson's disease) or diseases associated with dysregulation of the immune system.